Lyell Immunopharma announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to LYL314 for treating relapsed and/or...

Predictive Oncology leveraged its AI-driven drug discovery platform and biobank of live-cell tumor samples to identify new potential uses...

Oryzon Genomics has initiated a Phase I/II trial evaluating iadademstat, an LSD1 inhibitor, combined with immune checkpoint inhibitors (atezolizumab...

AI is making significant strides in the rapidly evolving field of clinical trials. Dominique Demolle, CEO of Cognivia, shares...

Johnson & Johnson’s oral IL-23 receptor antagonist, icotrokinra (JNJ-2113), demonstrated positive Phase 3 results in treating moderate-to-severe plaque psoriasis....

MISTR, the largest LGBTQ+ sexual health platform in the U.S., reports a significant 50% drop in STI positivity rates...

BioCardia announced that Emory University School of Medicine is enrolling patients in the Phase III CardiAMP HF II trial,...

ImPact Biotech will present updated preliminary results from its Phase 3 ENLIGHTED study of Padeliporfin VTP in patients with...

Verve Therapeutics has received FDA Fast Track designation for VERVE-102, a gene editing medicine designed as a single-course treatment...

Vantage Biosciences has initiated a Phase 2 clinical trial of VX-01, an oral therapy for non-proliferative diabetic retinopathy (NPDR)....